A Phase I Study of IM-1021 in Participants with Advanced Malignancies
Categories (click each to see list of all clinical trials associated with that category): Lymphoma/CLL (ONC), Pancreatic Cancer Center of Excellence - PCCE (ONC), Sarcoma (ONC), Thoracic (ONC)
Current Status: Open
Phase: I
Principal Investigator: Lunning, Matthew
Contact Information:
Megan Edwards
megan.edwards@unmc.edu
Eligibility: https://clinicaltrials.gov/study/NCT06823167?term=NCT06823167&rank=1#participation-criteria
Summary
Primary:
To evaluate the safety and tolerability of IM-1021 in participants with advanced lymphomas and advanced solid tumors
To determine the recommended dose(s) and schedule(s) of IM-1021 for further development
Secondary:
To characterize the pharmacokinetics (PK) of IM-1021 in participants with advanced lymphomas and advanced solid tumors
To characterize the immunogenicity of IM-1021
To evaluate the preliminary anti-tumor activity of IM-1021 in participants with advanced lymphomas and advanced solid tumors
Exploratory:
To evaluate additional preliminary anti-tumor activity of IM-1021 in participants with advanced lymphomas and advanced solid tumors
To assess the association between circulating biomarkers and IM-1021 anti-tumor activity
To assess the association between ROR1 expression and IM-1021 anti-tumor activity
To assess the association between anti-tumor activity and tumor biomarkers